Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Neuroendocrine Carcinoma
- Oncology
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: The study is a randomised controlled trial. One hundred and two eligible participants will be randomised (1:1)Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03837977
- Collaborators
- University of Leeds
- Servier
- National Institute for Health Research, United Kingdom
- Investigators
- Principal Investigator: Mairead McNamara The Christie NHS Foundation Trust, The University of Manchester